Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) precocious reported quarterly results that work similar 2 scripts from other ends of pharma. Lilly posted 55.55% gross maturation from a presumption of strength. Pfizer is inactive rebuilding from the COVID cliff. Their M&A playbooks archer the story.

Blowout Quarter Meets a Methodical Rebuild

Lilly's Q1 2026 gross deed $19.799 billion, adjusted EPS came successful astatine $8.55 against a $6.79 estimate, and absorption raised full-year gross guidance to $82.0 cardinal to $85.0 billion. Mounjaro unsocial produced $8.662 billion, up 125%, and Zepbound added $4.160 billion. CEO David Ricks framed it bluntly: "2026 is disconnected to a beardown start...we besides delivered pipeline advancement crossed each 4 therapeutic areas and continued investing successful Lilly's aboriginal maturation done 4 acquisitions."

Pfizer's Q4 2025, by contrast, was a fix-the-foundation quarter. Revenue of $17.56 cardinal slipped 1.2% twelvemonth implicit year, but the non-COVID portfolio grew 9% operationally. Eliquis, Vyndaqel, and Prevnar each posted astir 10% growth. Comirnaty fell 33% and Paxlovid 70%, precisely the spread Albert Bourla is trying to plug.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Eli Lilly wasn't 1 of them. Get them present FREE.

Offensive Bolt-Ons Versus Defensive Big Bets

Lilly is buying capableness from strength: AI cause find via Insilico's Pharma.AI platform, positive an Nvidia AI co-innovation lab. Pfizer is buying gross replacement, having entered obesity lone aft losing the Metsera bidding conflict with Novo Nordisk and discontinuing its ain oral GLP-1 danuglipron.

The Patent Cliff Decides Who Wins

The manufacture faces 190+ products losing exclusivity and implicit $300 cardinal successful income astatine hazard by 2030. Pfizer's ain $1.5 cardinal loss-of-exclusivity deed successful 2026 and 2026 EPS usher of $2.80 to $3.00 amusement the pressure. Vyndamax hold to 2031 and the caller Veppanu support bargain time. Lilly's Foundayo FDA approval, the lone anytime oral GLP-1, positive retatrutide Phase 3 wins widen the franchise good past the cliff.